Explore

Trendline Trendline
FDA Demands Safety Data for Lilly's Oral GLP-1 Drug Foundayo

FDA Demands Safety Data for Lilly's Oral GLP-1 Drug Foundayo

FDA Demands Safety Data for Lilly's Oral GLP-1 Drug Foundayo
Trendline Trendline
Eli Lilly's Foundayo Demonstrates Safety and Efficacy in ACHIEVE-4 Trial for Type 2 Diabetes

Eli Lilly's Foundayo Demonstrates Safety and Efficacy in ACHIEVE-4 Trial for Type 2 Diabetes

Eli Lilly's Foundayo Demonstrates Safety and Efficacy in ACHIEVE-4 Trial for Type 2 Diabetes
Trendline Trendline
FDA Requests Additional Safety Data for Eli Lilly’s New Obesity Drug Foundayo

FDA Requests Additional Safety Data for Eli Lilly’s New Obesity Drug Foundayo

FDA Requests Additional Safety Data for Eli Lilly’s New Obesity Drug Foundayo
Trendline Trendline
GoodRx Stock Rises Amid New Pricing for Wegovy HD

GoodRx Stock Rises Amid New Pricing for Wegovy HD

GoodRx Stock Rises Amid New Pricing for Wegovy HD
Trendline Trendline
Eli Lilly Confirms Safety of Foundayo in ACHIEVE-4 Trial, Aiming for Diabetes Approval

Eli Lilly Confirms Safety of Foundayo in ACHIEVE-4 Trial, Aiming for Diabetes Approval

Eli Lilly Confirms Safety of Foundayo in ACHIEVE-4 Trial, Aiming for Diabetes Approval
Trendline Trendline
FDA Demands Safety Data for Eli Lilly's Oral GLP-1 Drug Foundayo Amidst Market Competition

FDA Demands Safety Data for Eli Lilly's Oral GLP-1 Drug Foundayo Amidst Market Competition

FDA Demands Safety Data for Eli Lilly's Oral GLP-1 Drug Foundayo Amidst Market Competition
Trendline Trendline
Novo Nordisk CEO Highlights AI Partnership to Enhance Drug Discovery and Delivery

Novo Nordisk CEO Highlights AI Partnership to Enhance Drug Discovery and Delivery

Novo Nordisk CEO Highlights AI Partnership to Enhance Drug Discovery and Delivery
Trendline Trendline
Novo Nordisk Partners with OpenAI to Accelerate AI-Driven Drug Development

Novo Nordisk Partners with OpenAI to Accelerate AI-Driven Drug Development

Novo Nordisk Partners with OpenAI to Accelerate AI-Driven Drug Development
Trendline Trendline
Novo Nordisk Partners with OpenAI to Transform Drug Discovery and Development

Novo Nordisk Partners with OpenAI to Transform Drug Discovery and Development

Novo Nordisk Partners with OpenAI to Transform Drug Discovery and Development
Trendline Trendline
Novo Nordisk and OpenAI Collaborate to Enhance AI-Driven Drug Discovery

Novo Nordisk and OpenAI Collaborate to Enhance AI-Driven Drug Discovery

Novo Nordisk and OpenAI Collaborate to Enhance AI-Driven Drug Discovery
Trendline Trendline
San Diego Startup Neomorph Secures $100 Million Investment for Cancer Drug Development

San Diego Startup Neomorph Secures $100 Million Investment for Cancer Drug Development

San Diego Startup Neomorph Secures $100 Million Investment for Cancer Drug Development
Trendline Trendline
Novo Nordisk Partners with OpenAI to Accelerate Drug Discovery and Development

Novo Nordisk Partners with OpenAI to Accelerate Drug Discovery and Development

Novo Nordisk Partners with OpenAI to Accelerate Drug Discovery and Development